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Abstract
Background: Curative radiotherapy or chemoradiation for head and neck cancer (HNC) may result in severe acute and late
side effects, including tube feeding dependence. The purpose of this prospective cohort study was to develop a
prediction model for tube feeding dependence 6 months (TUBEM6) after curative (chemo-) radiotherapy in HNC patients.
Patients and Methods: Tube feeding dependence was scored prospectively. To develop the multivariable model, a group
LASSO analysis was carried out, with TUBEM6 as the primary endpoint (n = 427). The model was then validated in a test
cohort (n = 183). The training cohort was divided into three groups based on the risk of TUBEM6 to test whether the model
could be extrapolated to later time points (12, 18 and 24 months).
Results: Most important predictors for TUBEM6 were weight loss prior to treatment, advanced T-stage, positive N-stage,
bilateral neck irradiation, accelerated radiotherapy and chemoradiation. Model performance was good, with an Area under
the Curve of 0.86 in the training cohort and 0.82 in the test cohort. The TUBEM6-based risk groups were significantly
associated with tube feeding dependence at later time points (p,0.001).
Conclusion: We established an externally validated predictive model for tube feeding dependence after curative
radiotherapy or chemoradiation, which can be used to predict TUBEM6.
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Introduction
Patients with head and neck cancer (HNC) often receive
intensive anticancer treatment such as radiotherapy as single
modality or in combination with chemotherapy and/or targeted
agents such as cetuximab. Many patients may have severe
difficulties maintaining adequate nutritional intake prior to
treatment. This is caused by local tumor growth, which leads to
swallowing dysfunction, trismus, odynophagia, dysgeusia and
aspiration. In addition, anticancer therapy causes severe side
effects such as acute mucositis and xerostomia inducing swallowing
dysfunction. After completing such therapy, a substantial propor-
tion of patients without baseline swallowing dysfunction ultimately
develop persistent or even progressive swallowing dysfunction. In
some cases they require tube feeding for a long period of time [1].
Recently it was shown that swallowing dysfunction has a major
impact on health-related quality of life [2]. With grade III–IV
swallowing dysfunction according to the RTOG Late Radiation
Morbidity Scoring System, the most important general dimensions
of health-related quality of life were moderately to severely
affected. Moreover, swallowing dysfunction has been associated
with psychological distress not only in patients themselves, but also
in their spouses [3]. These results demonstrate that swallowing
dysfunction in general, and tube feeding dependence in particular,
are clinically relevant long-term side effects after curative (chemo-)
radiotherapy.
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Moreover, high-intensity treatment regimens have resulted in
improved survival, but with higher rates of tube feeding
dependence in these survivors [4,5]. The prevalence of patients
with long-term tube feeding dependence is therefore expected to
increase.
Previous studies have shown that the dose to the larynx and
pharyngeal musculature in radiotherapy treatment of HNC is
associated with the risk of long-term swallowing dysfunction [6–8]
and are considered swallowing organs at risk. Advanced radiation
delivery techniques such as intensity modulated radiotherapy
(IMRT) have been used to reduce the radiation dose to the
swallowing organs at risk [9]. Promising results have been reported
on the use of swallowing exercises before and during treatment to
reduce the risk of persisting swallowing dysfunction after curative
(chemo-) radiation [10,11]. Thus, predictive models that can
identify patients at increased risk of tube feeding dependence after
curative (chemo-) radiotherapy before starting treatment would
allow selection of suitable candidates for preventive strategies, such
as swallowing sparing IMRT and/or preventive swallowing
exercises.
Therefore, the main purpose of this study was to develop a
prediction model for tube feeding dependence after curative
(chemo-) radiotherapy in HNC based on pretreatment character-
istics that can be used to improve selection of patients, prior to
treatment, for these preventive measures and/or support decision
making with regard to the treatment strategy in an early stage (e.g.
definitive radiotherapy versus primary surgery). This prediction
model was validated in an external and independent prospective
cohort to further support its general applicability.
Material and Methods
Ethics statement
All patients were subjected to a prospective data registration
program in which complications and treatment results in terms of
local control and survival are prospectively assessed. This is done
within the framework of routine clinical practice in which outcome
and complications are systemically scored as part of a quality
assurance program. All data obtained and used for this study has
been anonymized.
The (Dutch) Medical Research Involving Human Subjects Act
is not applicable to data collection as part of routine clinical
practice and use of these data for scientific papers regarding the
quality assurance program. Only research that is within the scope
of the Medical Research Involving Human Subjects Act needs
approval from an (accredited) ethics committee. Therefore, the
hospital ethics committee (the Medisch Ethische Toetsingscom-
missie; METc) concluded that data collection by this program is
regarded as part of routine patient care and granted us a waiver
from needing ethical approval for the conduct of this study.
In the Netherlands a patient of course has to give his/her
consent for the collection of the extra data on behalf of the quality
assurance program and the use of these data for scientific papers
regarding the quality assurance program. However, according to
Dutch legislation, consent is free of form, and verbal consent is
sufficient. Therefore, patients were asked to participate in this
quality assurance program and asked for permission to use their
data for the program and scientific papers regarding the program.
Refusal of participation was recorded in their medical record.
Patients
The population of this prospective cohort study was composed
of 610 consecutive patients with carcinoma of the mucosal surfaces
of the larynx, oropharynx, oral cavity, hypopharynx and
nasopharynx, who received curative radiotherapy with or without
chemotherapy or cetuximab. Data from patients treated at our
hospital were used to develop the prediction model (training
cohort: 427 patients), while data from patients treated at another
hospital were used to externally validate the model (test cohort:
183 patients).
Baseline weight loss was defined as the percentage of total body
weight lost during the 6 months prior to radiation, with 1 to 10%
weight loss defined as moderate and more than 10% defined as
severe weight loss.
As we were primarily interested in radiation-induced swallowing
dysfunction, patients that used a feeding tube at baseline were
excluded from this analysis (RTOG grade 3–4). Moreover,
patients had to be free of local recurrence or distant metastases
at the time of assessment of swallowing dysfunction.
Treatment
All patients were treated either with conventional 3D conformal
radiotherapy (3D-CRT) or IMRT. The dose to the parotid glands
was reduced as much as possible. In the cohorts included in this
analysis, no dose constraints for the swallowing organs at risk were
used.
Patients undergoing concomitant chemoradiotherapy were
treated with conventional fractionation (2.0 Gray (Gy) per
fraction, 5 times per week up to 70 Gy in 7 weeks). Patients with
stage I–II and stage III–IV tumors who were considered ineligible
for (chemo-) radiotherapy were treated with accelerated radio-
therapy with a concomitant boost technique (2.0 Gy per fraction, 6
times per week up to 70 Gy in 6 weeks). Since 2008, patients with
locally advanced (stage III–IV) tumors, for whom chemotherapy
was considered infeasible, have been treated with cetuximab using
a loading dose of 400 mg/m2 one week prior to radiotherapy and
a weekly dose of 250 mg/m2 during accelerated radiotherapy (2.0
Gy per fraction, 6 times per week up to 70 Gy in 6 weeks).
In the training cohort, concomitant chemotherapy consisted of
cisplatin 100 mg/m2 on days 1, 22 and 43. In the test cohort,
concomitant chemotherapy consisted of 3 cycles of carboplatin
(300–350 mg/m2) on day 1 and 5-fluorouracil (5-FU) on days 1 to
4 as a continuous infusion (600 mg/m2/24 hours) every 3 weeks.
At both institutions, prophylactic PEG tube placement was
standard of care in all patients treated with curative concomitant
chemoradiation and patients were instructed to refrain from using
the PEG-tube. In patients with significant weight loss (.5% weight
loss in 1 month or.10% in 6 months or BMI,18.5 kg/m2) and/
or low nutritional intake (less than half of daily requirements for
energy, proteins or fluids) and/or severe swallowing dysfunction
prior to treatment, PEG tubes were placed prior to treatment.
However, these patients were excluded from the analysis.
Reactive placement of feeding tubes was used for patients with
significant weight loss or swallowing dysfunction during treatment;
in this situation a nasogastric feeding tube was placed during
treatment if swallowing problems were considered temporarily and
expected to recover soon. In case of severe swallowing problems
early during treatment and/or expected to sustain for a longer
period of time, there was a preference for PEG-tube placement.
Follow up schedule and assessments
In both hospitals, acute and late radiation-induced side effects
were prospectively assessed according to the RTOG/EORTC
Acute and Late Radiation Morbidity Scoring System. Tube
feeding dependence was scored separately. For the present
analysis, the primary endpoint was tube feeding, either with
PEG (percutaneous endoscopic gastrostomy) or nasogastric tube at
6 months after completion of treatment (TUBEM6). Patients were
Prediction Model for Tube Feeding Dependence
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considered tube feeding dependent if a feeding tube was present
and used because oral intake was limited or impossible.
Definition of risk groups
The total population of the training cohort was divided into
three risk groups based on the risk on TUBEM6. The division into
low, intermediate and high risk groups was arbitrary: patients were
considered low risk when the probability for TUBEM6 was #5%,
intermediate risk when this value was .5–15% and high risk for
values .15%. To determine whether the model could be
extrapolated for the same patients at later time points, the positive
and negative predictive values for TUBEM6 were calculated at 12,
18 and 24 months.
Statistics
After the regression analysis, the variance inflation factor was
calculated to check for high correlations between candidate
prognostic variables. There were no high correlations and,
therefore, no changes were made to the variables.
For the development of the prediction model the least absolute
shrinkage and selection operator (LASSO) method was used,
which is a logistic regression analysis with a bound on the absolute
magnitude of the regression coefficients [12]. This method
includes all variables in the modeling process but only a subset
of predictor variables are eventually included in the model, setting
the coefficients of variables that have negligible effects to zero. The
LASSO method has been successfully applied to build Normal
Tissue Complication (NTCP) models for HNC patients [13].
Given the inclusion of categorical variables in the current data, the
group-LASSO (variant of LASSO) was used for building the
prediction models. The amount of shrinkage was selected by
optimizing the Bayesian information criterion (BIC) over the
regularization path.
The environment for statistical computing R (R Development
Core Team, R: A language and Environment for statistical
Computing, Version 2.15, Vienna, 2012) was used to do the
calculation. The package ‘grpreg’ was used to build the group-
LASSO model.
For the selected variables xi and their fitted coefficients bi, the









Model performance was described using different validation
measures [14,15]. The discriminating ability of the model was
described by the area under the curve (AUC) value based on the
Receiver Operating Characteristics curve. The discrimination
slope was calculated as the absolute difference between the mean
predicted NTCP value for patients with and without the outcome.
The calibration of the model reflects the agreement between
observed outcomes and predictions. The calibration slope and
intercept were calculated as described by Miller et al. [16]. To
evaluate whether the model performance measures based on the
observed outcomes differed from their expected values, we used
Monte-Carlo to generate the expected distributions and calculated
p-values. Finally, a Hosmer-Lemeshow test with 10 groups was
performed to evaluate the calibration of the model.
Results
Univariate analysis of the training cohort
The training cohort consisted of 427 patients, 77% male and
23% female with a mean age of 62 years. The pretreatment
characteristics of the patients are listed in Table 1. Out of 427
patients, 55 (12.9%) were tube feeding dependent at 6 months
after completion of treatment. In the univariate analysis, younger
age, higher T-classification, higher N-classification, primary tumor
site other than the larynx, concomitant chemoradiation, bilateral
irradiation, weight loss at baseline and swallowing dysfunction at
baseline were significantly associated with TUBEM6 (Table 2).
Group-LASSO analysis in training cohort
The LASSO analysis arrived at a multivariable model
containing 5 variables with non-zero coefficients: weight loss prior
to treatment, T-classification and N-classification, bilateral irradi-
ation of the neck, and treatment modality, including accelerated
radiotherapy and chemoradiotherapy (Table 3).





where S=23.69 + (T-stage * 1.01) + (N-stage * 0.87) + (moderate
weight loss * 0.82) + (severe weight loss * 1.51) + (bilateral neck irradiation
* 0.35) + (accelerated radiotherapy * 0.25) + (chemoradiotherapy * 0.41)
The risk of TUBEM6 can also be estimated by using the
nomogram (Figure 1). In the training cohort, model performance
was excellent, with an AUC of 0.86 The discrimination slope had
a value of 0.21. The Hosmer-Lemeshow chi square had a value of
9.35 (p-value 0.3) indicating good agreement between expected
and observed rates.
External validation
The test cohort consisted of 183 patients, 73% male and 27%
female, with a mean age of 62 years. The training and test cohort
differed significantly with regard to T-classification, N-classifica-
tion, the applied treatment modalities and radiation techniques,
and weight loss at baseline (Table 1). Out of 183 patients, 27
(14.8%) were tube feeding dependent at 6 months after completion
of treatment. Model performance in the external test cohort was
good, with an AUC of 0.82 (Expected: 0.80, 95% CI: 0.72–0.86,
p-value: 0.8) and a discrimination slope of 0.20 (Expected: 0.19,
95% CI: 0.13–0.25, p-value 0.6). The calibration graph (Figure
S1) illustrates that the observed NTCP-values of TUBEM6 in the
test cohort are in close proximity of the predicted NTCP-values.
The Hosmer-Lemeshow test showed no statistically significant
difference between predicted and measured outcomes in the test
cohort (Table S1).
Relationship with tube feeding dependence at
subsequent time points
The prevalence of tube feeding dependence was 6.9% (23 of
335 patients at risk) at 12 months (TUBEM12), 3.6% (9 of 251
patients at risk) at 18 months (TUBEM18) and 4.0% (8 of 200
patients at risk) at 24 months (TUBEM24). TUBEM6 was very
predictive for tube feeding dependence at later time points. The
negative predictive values of TUBEM6 for TUBEM12, TUBEM18,
TUBEM24 were 97.1%, 99.1% and 98.9%, respectively, indicating
that almost all patients who were not tube feeding dependent at 6
months remained independent at subsequent time points. The
positive predictive values of TUBEM6 for TUBEM12, TUBEM18,
Prediction Model for Tube Feeding Dependence
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TUBEM24 were 50.0%, 36.8% and 40.0%, respectively, indicating
recovery from tube feeding dependence in more than half of the
patients.
Discussion
The purpose of the current study was to develop and validate a
prediction model for tube feeding dependence 6 months after
curative (chemo-) radiotherapy in HNC patients. Such a model
could be used in clinical practice to predict which patients are at
risk for long-term tube feeding dependence, prior to treatment,
and would thus be suitable candidates for preventive measures
such as swallowing exercises and/or swallowing sparing IMRT.
In the LASSO analysis, five independent prognostic factors for
TUBEM6 were identified: advanced T-stage (T3–T4), positive N-
stage, weight loss at baseline, bilateral irradiation of the neck, and
treatment modality. Model performance in both the training
cohort and the test cohort from another hospital was good to
excellent, which confirms the generalization ability of the model.
A prediction model as presented in this study is increasingly
desirable due to the more aggressive treatment regimens that are
being used in HNC, including altered fractionation schedules for
radiotherapy, concomitant (chemo-) radiotherapy or both. These
intensive cancer treatments have improved loco-regional control
and overall survival [17–19] but at the expense of an increase in
radiation-induced side effects [20] in particular long-term swal-
lowing dysfunction [21].
Prophylactic feeding tube placement is standard practice in
many institutions to avoid treatment interruptions and unplanned
Table 1. Pre-treatment charactistics in the training cohort and test cohort.
Variable
Training cohort
(n=427) Test cohort (n =183) P-value
Number % Number %
Sex Male 329 77% 134 73% p=0.311
Female 98 23% 49 27%
Age 18–65 years 269 63% 117 64% p=0.826
.65 years 158 37% 66 36%
T-classification Tis-T1 129 30% 33 18% p=0.002
T2 157 37% 74 40%
T3 88 21% 36 20%
T4 53 12% 40 22%
N-classification N0 291 68% 88 48% p,0.001
N1 36 8% 19 10%
N2a 9 2% 6 3%
N2b 40 9% 16 9%
N2c 42 10% 48 26%
N3 9 2% 6 3%
Primary site Larynx 242 57% 91 50% p=0.282
Oropharynx 103 24% 59 32%
Oral cavity 28 7% 10 6%
Hypopharynx 33 8% 16 9%
Nasopharynx 21 5% 7 4%
Treatment modality Conventional radiotherapy 148 35% 12 6% p,0.001
Accelerated radiotherapy 204 48% 131 72%
Chemoradiation 75 17% 40 22%
Radiation technique 3D-CRT 379 89% 77 42% p,0.001
IMRT 48 11% 106 58%
Neck irradiation Primary alone 106 25% 40 22% p=0.496
Primary + ipsilateral neck 33 8% 11 6%
Primary + bilateral neck 288 67% 132 72%
Weigh loss at baseline No weight loss 320 75% 113 62% p=0.002
Weight loss 1–10% 84 20% 50 27%
Weight loss .10% 23 5% 20 11%
Baseline swallowing No swallowing problems 338 79% 148 81% p=0.601
(grading according to RTOG) Mild swallowing problems, soft diet 76 18% 32 18%
Moderate swallowing problems, liquid diet 13 3% 3 2%
Abbreviations: 3D-CRT, Three Dimensional Conformal Radiotherapy; IMRT, Intensity-Modulated Radiation Therapy; RTOG, Radiation Therapy Oncology Group.
doi:10.1371/journal.pone.0094879.t001
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hospitalizations because of compromised nutritional intake and/or
dehydration [22]; adequate nutrition has been shown to improve
tolerance and response rates to (chemo-) radiotherapy [23].
However, others have shown that pretreatment feeding tube
placement may lead to increased long-term swallowing dysfunc-
tion, longer feeding tube duration and the need for pharyngo-
esophageal dilatation [24]. In addition, long-term feeding tube
dependence may significantly reduce quality of life after treatment
for HNC [22,25]. Terrell et al. [26] showed that feeding tube
dependence was the strongest clinical predictor of negative effects
on health-related quality of life relative to other medical co-
morbidities. It was associated with significantly lower scores on 10
out of 12 collective domains in the Medical Outcomes Study Short
Form 36-item Health Survey and HNC quality-of-life instruments.
As already mentioned, at both institutions, prophylactic PEG tube
placement was standard of care in all patients treated with curative
concomitant chemoradiation and patients were instructed to
refrain from using the PEG-tube. In patients with significant
weight loss (.5% weight loss in 1 month or .10% in 6 months or
BMI ,18.5 kg/m2) and/or low nutritional intake (less than half of
daily requirements for energy, proteins or fluids) and/or severe
swallowing dysfunction prior to treatment, PEG tubes were placed
prior to treatment. However, these patients were excluded from
the analysis.
Chemoradiotherapy was a prognostic factor in the LASSO
analysis. It should be stressed that given the fact that all patients
receiving concomitant chemoradiation received prophylactic PEG
tube placement, the Odds ratio of 1.51 should be considered the
results of this preset combination and that no conclusions can be
drawn with regard to these two factors separately. However, given
this Odds ratio of 1.51 and the Odds ratio of 1.28 found for
accelerated radiotherapy (without prophylactic PEG-tube place-
ment), we believe that the contribution of prophylactic PEG tube
feeding is probably limited or absent.
The training cohort and test cohort were from two different
hospitals with different chemotherapy regimens in each hospital.
In the training cohort, cisplatinum was used while in the test
cohort 5-FU in combination with carboplatin was used. The
model performance in both cohorts was comparable, which
indirectly confirms that there will probably be no major difference
between the two chemotherapy regimens.
Given that both advanced T-stage (larger tumors) and N-stage
and bilateral irradiation of the neck were prognostic factors for
feeding tube dependence at 6 months after (chemo-) radiotherapy,
it can be hypothesized that the risk of tube feeding dependence is
Table 2. Results of the univariate logistic regression analysis with tube feeding dependence at 6 months (TUBEM6) as primary
endpoint in patients included in the training cohort.
Variable Univariate analysis
Odds ratio (95% CI) P-value
Sex Male 1.00
Female 1.61 (0.86–3.00) p = 0.135
Age .65 years 1.00
18–65 years 2.32 (1.18–4.54) p = 0.014
T-classification Tis-T2 1.00
T3–T4 10.02 (5.08–19.78) p,0.001
N-classification N0 1.00
N+ 7.67 (4.05–14.50) p,0.001
Primary site Larynx 1.00
Oral cavity 8.63 (2.92–25.51) p,0.001
Oropharynx 8.74 (3.93–19.47) p,0.001
Nasopharynx 6.09 (1.70–21.83) p = 0.006
Hypopharynx 9.71 (3.52–26.79) p,0.001
Treatment modality Conventional radiotherapy 1,00
Accelerated radiotherapy 1.77 (0.79–3.99) p = 0.167
Chemoradiation 7.72 (3.38–17.67) p,0.001
Radiation technique 3D-CRT 1.00
IMRT 1.67 (0.76–3.67) p = 0.202
Neck irradiation Local or unilateral irradiation 1.00
Bilateral irradiation 15.45 (3.71–64.39) p,0.001
Baseline swallowing Grade 0 1.00
(grading according to RTOG) Grade 1–2 3.20 (1.62–6.32) p = 0.001
Weight loss No weight loss 1.00
(baseline) 1–10% 5.66 (2.93–10.94) p,0.001
.10% 16.36 (6.42–41.68) p,0.001
Abbreviations: 3D-CRT, Three Dimensional Conformal Radiotherapy; IMRT, Intensity-Modulated Radiation Therapy; RTOG, Radiation Therapy Oncology Group; CI,
Confidence Interval.
doi:10.1371/journal.pone.0094879.t002
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related to the radiation dose distribution in the anatomical
structures involved in swallowing, such as the pharyngeal
constrictor muscles. A number of authors indeed showed a dose-
volume-effect relationships of anatomical structures involved in
swallowing and swallowing dysfunction after (chemo-) radiother-
apy, such as the pharyngeal constrictor muscles [8,27–29].
Accelerated radiotherapy was also an independent prognostic
factor for tube feeding dependence. These results are in line with
those presented by Overgaard et al. who showed that accelerated
radiotherapy lead to more frequent and longer persisting confluent
mucositis than the conventionally treated group and consequently
long-term dysphagia [30]. Another more recent updated study,
however, showed that accelerated RT does increase acute but not
late morbidity, including dysphagia [31].
In the current study, baseline weight loss was also an
independent prognostic factor for tube feeding dependence. This
Table 3. Results of the LASSO analysis with tube feeding dependence at 6 months (TUBEM6) as primary endpoint.
Variable B 95% CI of B OR P-value
T-classification
T3–T4 vs. Tis-T2 1.01 (0.79–1.32) 2.75 p,0.001
N-classification
N+ vs. N0 0.87 (0.65–1.10) 2.39 p,0.001
Weight loss (baseline)
1–10% weight loss vs. no weight loss 0.82 (0.65–0.99) 2.27 p,0.001
.10% weight loss vs. no weight loss 1.51 (1.19–1.83) 4.53 p,0.001
Neck irradiation
Bilateral vs. local/unilateral 0.35 (0.06–0.66) 1.42 p = 0.011
Treatment modality
Chemoradiation vs. conventional fractionation 0.41 (0.16–0.68) 1.51 p = 0.001
Accelerated fractionation vs. conventional fractionation 0.25 (0.10–0.41) 1.28 p = 0.001
Constant 23.69 (24.19–23.21)
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; B, model coefficient beta.
doi:10.1371/journal.pone.0094879.t003
Figure 1. Nomogram for tube feeding dependence to determine normal tissue complication probability (NTCP) values for each
individual patient. Abbreviations: SF, conventional radiotherapy; ART, accelerated radiotherapy; CRT, chemoradiation.
doi:10.1371/journal.pone.0094879.g001
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is in accordance with a previous report [1] in which baseline
weight loss was shown to be an independent prognostic factor for
grade 2–4 RTOG swallowing dysfunction at 6 months after
treatment. This suggests that a relatively high percentage of
baseline swallowing dysfunction is not recognized by radiation
oncologists and that swallowing dysfunction is therefore often
underreported, even in the case of prospective assessment of
toxicity.
From clinical practice we know that the reasons for feeding tube
placement are not solely related to swallowing problems, but may
be multifactorial. Nausea due to chemotherapy treatment, changes
in taste or saliva production and other factors may also necessitate
feeding tube placement. We did not directly take these factors into
account in this analysis since it was not possible to obtain
information about this for each individual patient. This is
something, however, that may have influenced feeding tube
placement and use in this patient group.
As the main purpose of the current analysis was to develop and
validate a multivariable prediction model that can be used to select
patients prior to treatment (i.e. during the preparation phase of
radiotherapy) for preventive measures, we did not take into
account candidate variables related to dose distributions in
swallowing organs at risk. This, however, will be investigated in
future research.
Our results show that TUBEM6 after treatment is predictive for
tube feeding dependence at later time points up to 24 months after
completion of radiotherapy. This is also in accordance with
previous reports [1], which showed that swallowing dysfunction at
6 months after curative (chemo-) radiation is highly predictive for
swallowing dysfunction at subsequent time points up to several
years after treatment.
Conclusion
The present study is the first to provide an externally validated
prediction model for tube feeding dependence after (chemo-)
radiation in a population-based cohort of patients with HNC. This
model enables clinicians to select patients that have not yet started
treatment, based on pretreatment characteristics, who are at
greatest risk for tube feeding dependence after treatment, and to
implement preventive strategies for them.
Supporting Information
Figure S1 Calibration plots for the predictive model for tube
feeding dependence at 6 months (TUBEM6) at internal validation
(A) and external validation (B).
(TIF)
Table S1 Performance of the prediction model for TUBEM6.
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